Iptacopan for serious conditions when other treatments fail
Treatments studied
Part of Blood & lymphatic clinical trials.
This program gives access to the drug iptacopan for patients with serious conditions who have no other options. It is not a standard clinical trial but a special way to get the drug when all approved treatments have failed or are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening condition.
- You must have no other approved treatment options that work for you, or none are suitable.
- You cannot be eligible for or currently in a Novartis clinical trial.
- Your doctor must request this drug for you as an individual patient.
- The treatment must be expected to help you more than it risks hurting you.
- It must be legal in your country to provide this drug through this special access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
This study looks at how well iptacopan works in everyday medical practice for people with paroxysmal nocturnal hemoglobinuria (PNH) being treated in Italy. It gathers information from routine care to understand real-world effectiveness.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Hear when a new C3 Glomerulopathy (C3G) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.